ENGLEWOOD CLIFFS, N.J., Aug. 1 /PRNewswire-FirstCall/ -- EpiCept Corporation today announced that it will host a conference call to discuss second quarter 2006 results and provide a business update on Thursday, August 3, 2006 at 9:00 a.m. Eastern Daylight Time. EpiCept will release results for the three and six months ended June 30, 2006, after the close of the market on Wednesday, August 2, 2006.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )
To participate in the live call, please dial (866) 425-6195 from the U.S. or Canada or (973) 935-2981 from international locations (please reference access code 7701005). The conference call will also be broadcast live on the Internet and may be accessed at http://www.epicept.com. The webcast will be archived for 90 days.
A telephone replay of the call will be available for seven days by dialing (877) 519-4471 from the U.S. and Canada or (973) 341-3080 from international locations (please reference reservation number 7701005).
About EpiCept Corporation
EpiCept is an emerging specialty pharmaceutical company focused on unmet needs in the treatment of pain and cancer. The Company has a staged portfolio with several pain therapies in late-stage clinical trials, and a lead oncology compound (for AML) with demonstrated efficacy in a Phase III trial; the compound is intended for commercialization in Europe. EpiCept is based in New Jersey, and the Company’s research and development team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding the efficacy, safety, and intended utilization of the Company’s respective product candidates, the conduct and results of future clinical trials, the sufficiency of our existing capital resources, plans regarding regulatory filings, future research and clinical trials, and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that EpiCept will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed in EpiCept’s periodic reports and other filings with the SEC.
EPCT-GEN
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comEpiCept Corporation
CONTACT: Robert W. Cook, of EpiCept Corporation, +1-201-894-8980,rcook@epicept.com; Francesca T. DeVellis, of Feinstein Kean Healthcare forEpiCept Corporation, +1-617-577-8110, francesca.devellis@fkhealth.com
Web site: http://www.epicept.com/
